Loading
Ocular Infections and Treatments · Journal article
Aaps Pharmscitech · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that examines the theoretical application of nanosuspensions—drug formulations dispersed in aqueous medium—as a strategy to improve ocular drug delivery and address limitations of topical eye drops caused by the blink reflex and tear clearance. The source identifies a therapeutic problem and proposes nanosuspensions as a potential solution, but does not report empirical clinical evidence, comparative efficacy data, or patient outcomes.
Narrative review. Patients with ocular infections affecting ocular surface, adnexal structures, or intraocular structures.
Topical eye drops instilled into the lower precorneal pocket are the most patient-compliant delivery method but lose efficacy due to the blink reflex Nanosuspensions disperse hydrophobic drugs in aqueous medium stabilised by surfactants, offering a promising strategy for mitigating ocular infections Ocular infections include surface/adnexal infections (blepharitis, conjunctivitis, keratitis, dacryocystitis, orbital infections) and intraocular infections from trauma or systemic disease
No information on safety, adverse events, or patient outcomes.
This review does not provide clinical evidence to support or guide treatment decisions. Clinicians should not rely on this source to inform infection management; it is an exploratory synopsis of a potential delivery technology rather than an evaluation of efficacy or safety.
This is a narrative review examining the potential applicability of nanosuspensions for ocular infection treatment; it raises questions about a delivery strategy rather than reporting empirical results or clinical evidence.
As stated by the source record.
This review does not provide clinical evidence to support or guide treatment decisions. Clinicians should not rely on this source to inform infection management; it is an exploratory synopsis of a potential delivery technology rather than an evaluation of efficacy or safety.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Ocular infections can affect the ocular surface and adnexal structures, intraocular structures, or both. Infections of the ocular surface and adnexa often arise from the invasion of commensals when typical barriers are compromised, which includes infectious blepharitis, conjunctivitis, keratitis, dacryocystitis, and orbital infections, among others. Intraocular infections may develop due to localised trauma or as part of a systemic condition. A variety of viruses, bacteria, fungi, protozoa, and helminths can cause intraocular illness. Occasionally, ocular abnormalities are the only external clinical indications of systemic infectious diseases. Analyzing specimens from ocular tissues or fluids can aid in diagnosing ocular infectious diseases and may help identify systemic infections. The management of ocular illnesses generally involves the topical application of antimicrobials and anti-inflammatory agents, along with targeted therapy addressing the underlying etiologies. In some cases, systemic antibacterial agents or glucocorticoids may be necessary. Addressing an inflamed or infected eye in an emergency context poses a diagnostic and therapeutic challenge for the emergency physician, with aetiology and prognoses varying from benign, self-limiting conditions to organ-threatening diseases. To address these ocular infections, the market has evolved with various therapeutics-based eye drops that are instilled specifically into the lower precorneal pocket and are regarded as the most patient-compliant method of drug delivery. Nevertheless, the efficacy of this approach is significantly reduced by the blink reflex, resulting in the loss of most of the topical dose. In this regard, nanosuspensions, which disperse hydrophobic drugs in an aqueous medium stabilised by surfactants, offer a promising strategy for mitigating ocular infections. Overall, this review aims to thoroughly examine the applicability of nanosuspensions in ocular drug delivery to target and treat infections in the human eye.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.